However, systemic or kidney-specific deletion of the Keap1 gene is not sufficient to cause an aggressive tumor formation, suggesting that NRF2 plays a role in supporting tumor growth and drug resistance, but not in tumorigenesis [64]. This evidence concerns the gene KEAP1 and neoplasm.